Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date

被引：26
|
作者：
Montemorano, Lauren [1 ]
Lightfoot, Michelle D. S. [2 ]
Bixel, Kristin [2 ]
机构：
[1] Ohio State Univ, Dept Obstet & Gynecol, Wexner Med Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, James Canc Hosp, Dept Obstet & Gynecol,Div Gynecol Oncol, Columbus, OH 43210 USA
来源：
ONCOTARGETS AND THERAPY | 2019年 / 12卷
关键词：
olaparib; PARP inhibitor; ovarian cancer; maintenance; DOUBLE-BLIND; THERAPY; CHEMOTHERAPY; BEVACIZUMAB; INHIBITORS; CARCINOMA;
D O I：
10.2147/OTT.S195552
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
PARP inhibitors have shown significant promise in the treatment of ovarian cancer. Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer in patients who have received multiple prior lines of chemotherapy. In this review, we focus on the use of olaparib in the maintenance setting including the evidence to date, ongoing research, and future directions.
引用
收藏
页码：11497 / 11506
页数：10
相关论文
共 50 条
  • [31] FDAApproval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer
    Arora, Shaily
    Balasubramaniam, Sanjeeve
    Zhang, Hui
    Berman, Tara
    Narayan, Preeti
    Suzman, Daniel
    Bloomquist, Erik
    Tang, Shenghui
    Gong, Yutao
    Sridhara, Rajeshwari
    Turcu, Francisca Reyes
    Chatterjee, Deb
    Saritas-Yildirim, Banu
    Ghosh, Soma
    Philip, Reena
    Pathak, Anand
    Gao, Jennifer J.
    Amiri-Kordestani, Laleh
    Pazdur, Richard
    Beaver, Julia A.
    ONCOLOGIST, 2021, 26 (01) : E164 - E172
  • [32] A Retrospective Analysis of Clinical Biomarkers for Olaparib Maintenance Therapy in Patients with Recurrent Ovarian Cancer
    Endo, Shun
    Shigeta, Shogo
    Tokunaga, Hideki
    Shimizu, Takanori
    Hasegawa-Minato, Junko
    Hashimoto, Chiaki
    Ishibashi, Masumi
    Nagai, Tomoyuki
    Shiga, Naomi
    Shimada, Muneaki
    Yaegashi, Nobuo
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2022, 258 (01) : 1 - 9
  • [33] Stem Cell Transplantation for Ovarian Cancer Patient with Associated Myelodysplasia After Maintenance Therapy with Olaparib: A Case Report
    Linn, Zeyar
    Gu, Zhongyi
    Wang, Libing
    Cai, Shengyun
    INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2025, 18 : 241 - 248
  • [34] Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer: The early experience in Taiwan
    Hsu, Chia-Chen
    Pan, Yu-Bin
    Lai, Chyong-Huey
    Chang, Ting-Chang
    Yang, Lan-Yan
    Chou, Hung-Hsueh
    TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2021, 60 (04): : 634 - 638
  • [35] Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design
    Poveda, Andres M.
    Davidson, Richard
    Blakeley, Christopher
    Milner, Alvin
    FUTURE ONCOLOGY, 2019, 15 (32) : 3651 - 3663
  • [36] Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)
    Perez-Fidalgo, J. A.
    Cortes, A.
    Guerra, E.
    Garcia, Y.
    Iglesias, M.
    Sarmiento, U. Bohn
    Garcia, E. Calvo
    Sanchez, L. Manso
    Santaballa, A.
    Oaknin, A.
    Redondo, A.
    Rubio, M. J.
    Gonzalez-Martin, A.
    ESMO OPEN, 2021, 6 (04)
  • [37] Newly diagnosed ovarian cancer: Which first-line treatment?
    Lorusso, Domenica
    Ceni, Valentina
    Daniele, Gennaro
    Salutari, Vanda
    Pietragalla, Antonella
    Muratore, Margherita
    Nero, Camilla
    Ciccarone, Francesca
    Scambia, Giovanni
    CANCER TREATMENT REVIEWS, 2020, 91
  • [38] Olaparib Tablet: A Review in Ovarian Cancer Maintenance Therapy
    Heo, Young-A
    Dhillon, Sohita
    TARGETED ONCOLOGY, 2018, 13 (06) : 801 - 808
  • [39] Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis
    Barrington, David A.
    Tubbs, Crystal
    Smith, Haller J.
    Straughn, J. Michael, Jr.
    Senter, Leigha
    Cohn, David E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (10) : 1569 - 1575
  • [40] Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials
    Ma, Jiao
    Deng, Hongyong
    Li, Jiajia
    Hu, Shaopu
    Yang, Yanping
    Liu, Sheng
    Han, Xianghui
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 3061 - 3078
12345